Fight CRC Clinical Trial Finder

Date Trial Added
View:
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags
NCT ID
NCT06455254
TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM Phase
Phase 2
Date Added
2024-06-12
Location
China
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Tags
MSS/ MMRp
NCT ID
NCT06415851
TitleChemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab Phase
Phase 2
Date Added
2024-05-15
Location
China
Prior IO Allowed
No
CRC-directed
Yes
Status
Not yet recruiting
Drugs
Tags
MSS/ MMRp
NCT ID
NCT06412198
TitleA Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations Phase
Phase 1, Phase 2
Date Added
2024-05-14
Location
Massachusetts, United States
Texas, United States
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Adagrasib, cemiplimab, cetuximab
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06336902
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer Phase
Phase 1
Date Added
2024-03-29
Location
California, United States
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Balstilimab, Botensilimab
Tags
MSS/ MMRp
NCT ID
NCT06322693
TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) Phase
Phase 1
Date Added
2024-03-21
Location
Arizona, United States
California, United States
Colorado, United States
Connecticut, United States
District of Columbia, United States
Florida, United States
Georgia, United States
Illinois, United States
Iowa, United States
Kansas, United States
Kentucky, United States
Maryland, United States
Massachusetts, United States
Michigan, United States
Minnesota, United States
New Jersey, United States
New York, United States
Ohio, United States
Oregon, United States
Pennsylvania, United States
South Carolina, United States
Tennessee, United States
Texas, United States
Virginia, United States
Washington, United States
Wisconsin, United States
Korea, Republic of
Spain
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06310564
TitleLow and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy Phase
Not Applicable
Date Added
2024-03-15
Location
Italy
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06300463
TitlePlatform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases Phase
Phase 2
Date Added
2024-03-08
Location
New York, United States
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
AGEN1423, Balstilimab, Botensilimab
Tags
MSS/ MMRp
NCT ID
NCT06302062
TitlePhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors Phase
Phase 1
Date Added
2024-03-08
Location
China
Prior IO Allowed
Yes
CRC-directed
No
Status
Recruiting
Drugs
Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06253520
TitleAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer Phase
Phase 1
Date Added
2024-02-12
Location
Maryland, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06218914
TitleA Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation Phase
Phase 1
Date Added
2024-01-23
Location
California, United States
Florida, United States
Illinois, United States
Kansas, United States
Missouri, United States
New York, United States
Pennsylvania, United States
Tennessee, United States
Texas, United States
Washington, United States
Wisconsin, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Tags
MSI-H/ MMRd, MSS/ MMRp